영양, 대사 및 감염에 미치는 프로톤펌프억제제의 영향: Safe 측면

키워드

참고문헌 (42)

1. Yang YX, "Safety of proton pump inhibitor exposure", Gastroenterology, 139, pp.1115~1127 (2010)
2. Kahrilas PJ, "American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease", Gastroenterology, 135, pp.1392~1413 (2008)
3. Sharma VR, "Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia", South Med J, 97, pp.887~889 (2004)
4. den Elzen WP, "Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals", Aliment Pharmacol Ther, 27, pp.491~497 (2008)
5. Howden CW, "Vitamin B12 levels during prolonged treatment with proton pump inhibitors", J Clin Gastroenterol, 30, pp.29~33 (2000)
6. Maton PN, "Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study", Gastroenterology, 97, pp.827~836 (1989)
7. Mitchell SL, "The association between antiulcer medication and initiation of cobalamin replacement in older persons", J Clin Epidemiol, 54, pp.531~534 (2001)
8. Ruscin JM, "Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a protonpump inhibitor", Ann Pharmacother, 36, pp.812~816 (2002)
9. Schenk BE, "Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels", Aliment Pharmacol Ther, 13, pp.1343~1346 (1999)
10. Termanini B, "Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome", Am J Med, 104, pp.422~430 (1998)
11. Schenk BE, "Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin", Aliment Pharmacol Ther, 10, pp.541~545 (1996)
12. Kapadia C, "Cobalamin (Vitamin B12) deficiency: is it a problem for our aging population and is the problem compounded by drugs that inhibit gastric acid secretion", J Clin Gastroenterol, 30, pp.4~6 (2000)
13. Wolters M, "Cobalamin: a critical vitamin in the elderly", Prev Med, 39, pp.1256~1266 (2004)
14. Stewart CA, "Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy", Aliment Pharmacol Ther, 12, pp.83~98 (1998)
15. Koop H, "Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy", J Clin Gastroenterol, 14, pp.288~292 (1992)
16. Epstein M, "Proton-pump inhibitors and hypomagnesemic hypoparathyroidism", N Engl J Med, 355, pp.1834~1836 (2006)
17. Cundy T, "Severe hypomagnesaemia in long-term users of proton-pump inhibitors", Clin Endocrinol (Oxf), 69, pp.338~341 (2008)
18. Kuipers MT, "Hypomagnesaemia due to use of proton pump inhibitors: a review", Neth J Med, 67, pp.169~172 (2009)
19. Mackay JD, "Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series", QJM, 103, pp.387~395 (2010)
20. Hoorn EJ, "A case series of proton pump inhibitor-induced hypomagnesemia", Am J Kidney Dis, 56, pp.112~116 (2010)
21. Richards JB, "Proton pump inhibitors: balancing the benefits and potential fracture risks", CMAJ, 179, pp.306~307 (2008)
22. Targownik LE, "Use of proton pump inhibitors and risk of osteoporosis-related fractures", CMAJ, 179, pp.319~326 (2008)
23. Geller JL, "Proton pump inhibitor therapy and hip fracture risk", JAMA, 297, pp.1429~ (2007)
24. Laine L, "Proton pump inhibitors and bone fractures", Am J Gastroenterol, 104(Suppl 2), pp.S21~S26 (2009)
25. Thomson AB, "Safety of the long-term use of proton pump inhibitors", World J Gastroenterol, 16, pp.2323~2330 (2010)
26. Moayyedi P, "Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm", Am J Gastroenterol, 103, pp.2428~2431 (2008)
27. Corley DA, "Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients", Gastroenterology, 139, pp.93~101 (2010)
28. Gulmez SE, "Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study", Arch Intern Med, 167, pp.950~955 (2007)
29. Sarkar M, "Proton-pump inhibitor use and the risk for community-acquired pneumonia", Ann Intern Med, 149, pp.391~398 (2008)
30. Sultan N, "Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials", Can J Gastroenterol, 22, pp.761~766 (2008)
31. Yildizdas D, "Occurrence of ventilatorassociated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole", J Crit Care, 17, pp.240~245 (2002)
32. Levy MJ, "Comparison of omeprazole and ranitidine for stress ulcer prophylaxis", Dig Dis Sci, 42, pp.1255~1259 (1997)
33. Kantorova I, "Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial", Hepatogastroenterology, 51, pp.757~761 (2004)
34. Yamanaka Y, "A study of 13 patients with gastric tube in place after esophageal resection: use of omeprazole to decrease gastric acidity and volume", J Clin Anesth, 13, pp.370~373 (2001)
35. Aseeri M, "Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients", Am J Gastroenterol, 103, pp.2308~2313 (2008)
36. Pépin J, "Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec", Clin Infect Dis, 41, pp.1254~1260 (2005)
37. Williams C, "Review article: proton pump inhibitors and bacterial overgrowth", Aliment Pharmacol Ther, 23, pp.3~10 (2006)
38. Thorens J, "Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study", Gut, 39, pp.54~59 (1996)
39. Lombardo L, "Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy", Clin Gastroenterol Hepatol, 8, pp.504~508 (2010)
40. Theisen J, "Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids", J Gastrointest Surg, 4, pp.50~54 (2000)
41. Lewis SJ, "Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole", Aliment Pharmacol Ther, 10, pp.557~561 (1996)
42. Spiegel BM, "Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors", Am J Gastroenterol, 103, pp.2972~2976 (2008)

관련 논문AI추천